Valrubicin-Loaded Immunoliposomes for Specific Vesicle-Mediated Cell Death in the Treatment of Hematological Cancers

Following the transplantation of human pediatric B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, or acute myeloid leukemia in immunodeficient NSG mice, investigators generated patient-derived xenograft models, which were treated with valrubicin-loaded immunoliposomes loaded with antibodies to target CD19, CD7 or CD33.